Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II retreament trial of NASVAC therapeutic vaccine in chronic hepatitis B carriers
jRCTs061200009Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ABX203 in Chronic Hepatitis B (CHB), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Reduction of HBsAg. Started Jul 2020; status: completed.
02
Drugs
ABX203
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCTs061200009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061200009.